Pharmaceuticals

Projected Growth of the Global Minimal Residual Disease Testing Market to Reach $2.91 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the minimal residual disease testing market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Minimal Residual Disease Testing Market By The End Of 2029?

The minimal residual disease testing market has experienced rapid expansion in recent years. It is projected to grow from $1.59 billion in 2024 to $1.8 billion in 2025, at a compound annual growth rate (CAGR) of 12.9%. The historical growth of this market can be attributed to factors such as advancements in cancer research, requirements for treatment monitoring, accumulating clinical evidence, regulatory support, and improvements in patient outcomes.

The minimal residual disease testing market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.91 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.8%. Factors contributing to this growth during the forecast period include the rising occurrence of cancer, progress in therapeutic methods, the growing adoption of precision medicine, a move towards earlier diagnosis, and the integration into healthcare systems. Key trends anticipated for the forecast period encompass the incorporation of liquid biopsy techniques, an emphasis on identifying relapse early, a broader application of MRD testing in clinical trials, increased use in pediatric cancer treatment, and partnerships for research and development.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp

Which Business Drivers Are Underpinning The Growth Of The Minimal Residual Disease Testing Market?

The minimal residual disease testing market is projected to grow in the coming period, driven by the increasing incidence of cancer. Cancer is characterized by some of the body’s cells multiplying uncontrollably and spreading to different parts of the body. Minimal residual disease testing is a highly sensitive technique primarily used to detect cancer cells and identify cancer stages in humans. This enables cancer patients to avert the disease early, thus invigorating the minimal residual disease testing market. For instance, reports from the American Cancer Society Inc., a US-based nonprofit organization, indicated that approximately 1.9 million new cancer cases were anticipated to be diagnosed in the United States in 2022, leading to an estimated 609,360 cancer-related deaths in the same year. Therefore, the rising prevalence of cancer is a significant factor boosting the growth of the minimal residual disease testing market.

What Are The Principal Segment Types In The Minimal Residual Disease Testing Market?

The minimal residual disease testing market covered in this report is segmented –

1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test

2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies

3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application

4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users

Subsegments:

1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR

2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)

3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry

How Are Industry Trends Steering The Expansion Of The Minimal Residual Disease Testing Market?

Product innovations represent a significant trend increasing in prominence within the minimal residual disease testing market. Key companies active in the minimal residual disease testing market are developing novel products to uphold their market standing. For example, in 2022, Twist Bioscience, a US-based synthetic biology and genomics company, introduced the Twist MRD Panel to propel research and development in the detection of minimal residual disease (MRD) during cancer screening. The Twist MRD Panel is a customizable array of genes designed to identify extremely low concentrations of residual cancer cells in a patient’s blood. This panel is crafted for high flexibility and customization, allowing its integration into a typical next-generation sequencing (NGS) workflow, which can pinpoint minimal residual disease (MRD) in just five days.

Which Companies Are Contributing Significantly To The Minimal Residual Disease Testing Market Growth?

Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-testing-global-market-report

Which Region Offers The Most Opportunity For Minimal Residual Disease Testing Market Expansion?

North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp

Browse Through More Reports Similar to the Global Minimal Residual Disease Testing Market 2025, By The Business Research Company

Healthcare Analytical Testing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/healthcare-analytical-testing-services-global-market-report

Automotive Testing Inspection And Certification Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automotive-testing-inspection-and-certification-global-market-report

Cold Plasma Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-plasma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795